Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients
SAN FRANCISCO, May 31, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, will present data that...